Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Cumulative Effect, Period of Adoption, Adjustment
Legacy Convertible Preferred Stock
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Cumulative Effect, Period of Adoption, Adjustment
Additional Paid-In Capital
Cumulative Effect, Period of Adoption, Adjustment
Cumulative Effect, Period of Adoption, Adjusted Balance
Common Stock
Cumulative Effect, Period of Adoption, Adjusted Balance
Additional Paid-In Capital
Cumulative Effect, Period of Adoption, Adjusted Balance
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjusted Balance
Accumulated Other Comprehensive (Loss) Income
Cumulative Effect, Period of Adoption, Adjusted Balance
Legacy Convertible Preferred Stock
Common Stock
In-process research and development
Common Stock
Additional Paid-In Capital
In-process research and development
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive (Loss) Income
In-process research and development
Total
BALANCE at Dec. 31, 2019 $ (436,533)                 $ 436,533                
BALANCE (in shares) at Dec. 31, 2019 (100,038,109)                 100,038,109                
BALANCE at Dec. 31, 2019   $ 13 $ 436,520 $ 436,533 $ 16 $ 453,242 $ (294,262) $ 75 $ 159,071     $ 3   $ 16,722 $ (294,262) $ 75   $ (277,462)
BALANCE (in shares) at Dec. 31, 2019   128,100,821     154,913,934             26,813,113            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Exercise of Common Stock options                           136       136
Exercise of Common Stock options (in shares)                       314,809            
Vesting of restricted Common Stock                           4       4
Vesting of restricted stock units (in shares)                       3,500,915            
Stock-based compensation expense                           2,333       2,333
Common Stock warrants issued                           211       211
Net loss                             (45,570)     (45,570)
Other comprehensive income (loss)                               (27)   (27)
BALANCE at Jun. 30, 2020                       $ 16   455,926 (339,832) 48   116,158
BALANCE (in shares) at Jun. 30, 2020                       158,729,658            
BALANCE at Mar. 31, 2020 $ (436,533)                 $ 436,533                
BALANCE (in shares) at Mar. 31, 2020 (100,038,109)                 100,038,109                
BALANCE at Mar. 31, 2020   $ 13 $ 438,037 $ 438,050 $ 16 $ 454,759 $ (316,066) $ (84) $ 138,625     $ 3   16,722 (316,066) (84)   (299,425)
BALANCE (in shares) at Mar. 31, 2020   130,138,012     156,951,125             26,813,113            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Exercise of Common Stock options                           4       4
Exercise of Common Stock options (in shares)                       28,173            
Vesting of restricted Common Stock                           2       2
Vesting of restricted Common Stock (in shares)                       1,750,360            
Stock-based compensation expense                           1,074       1,074
Common Stock warrants issued                           87       87
Net loss                             (23,766)     (23,766)
Other comprehensive income (loss)                               132   132
BALANCE at Jun. 30, 2020                       $ 16   455,926 (339,832) 48   116,158
BALANCE (in shares) at Jun. 30, 2020                       158,729,658            
BALANCE at Dec. 31, 2020                       $ 23   844,188 (328,277) (9)   515,925
BALANCE (in shares) at Dec. 31, 2020                       224,626,597            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Exercise of Common Stock options                           3,665       3,665
Exercise of Common Stock options (in shares)                       2,846,734            
Vesting of restricted Common Stock (in shares)                       112,030            
Vesting of restricted stock units (in shares)                       43,921            
Repurchase of shares for employee tax withholdings                           (145)       (145)
Repurchase of shares for employee tax withholdings (in shares)                       (9,172)            
Issuance of Common Stock for acquisitions                       $ 1   208,988       208,989
Issuance of Common Stock for acquisitions (in shares)                       9,049,338            
Issuance of common stock for acquired in-process research and development                         $ 4,300       $ 4,300  
Issuance of common stock for acquired in-process research and development (in shares)                     334,370              
Stock-based compensation expense                           6,216       6,216
Vesting of Trine Founder shares (in shares)                       1,850,938            
Exercise of warrants                       $ 2   320,567       320,569
Exercise of warrants (in shares)                       20,690,975            
Net loss                             (102,288)     (102,288)
Other comprehensive income (loss)                               113   113
BALANCE at Jun. 30, 2021                       $ 26   1,387,779 (430,565) 104   957,344
BALANCE (in shares) at Jun. 30, 2021                       259,545,731            
BALANCE at Mar. 31, 2021                       $ 25   1,326,945 (387,385) (21)   939,564
BALANCE (in shares) at Mar. 31, 2021                       252,436,919            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Exercise of Common Stock options                           3,485       3,485
Exercise of Common Stock options (in shares)                       2,683,506            
Vesting of restricted Common Stock (in shares)                       56,015            
Vesting of restricted stock units (in shares)                       28,656            
Repurchase of shares for employee tax withholdings                           (91)       (91)
Repurchase of shares for employee tax withholdings (in shares)                       (6,931)            
Issuance of Common Stock for acquisitions                       $ 1   49,141       49,142
Issuance of Common Stock for acquisitions (in shares)                       4,013,196            
Issuance of common stock for acquired in-process research and development                         $ 4,300       $ 4,300  
Issuance of common stock for acquired in-process research and development (in shares)                     334,370              
Stock-based compensation expense                           3,999       3,999
Net loss                             (43,180)     (43,180)
Other comprehensive income (loss)                               125   125
BALANCE at Jun. 30, 2021                       $ 26   $ 1,387,779 $ (430,565) $ 104   $ 957,344
BALANCE (in shares) at Jun. 30, 2021                       259,545,731